Redefining Oligometastatic Pancreatic Ductal Adenocarcinoma: Biology, Diagnosis, and Precision Multimodal Therapy

BACKGROUND: Given the dismal prognosis of metastatic pancreatic ductal adenocarcinoma, oligometastatic disease (OM-PDAC) has emerged as a distinct clinical entity, challenging systemic-only paradigms via advanced multimodal therapies. RECENT FINDINGS: Retrospective data indicate that anatomical burden alone inadequately guides patient selection. Optimal management requires integrating high-quality imaging, liquid biopsies, and molecular profiling to identify biologically favorable disease. Patients achieving durable responses to induction chemotherapy show improved survival following local interventions like conversion surgery, stereotactic radiotherapy, or ablation. CONCLUSION: OM-PDAC management must transition from anatomy-based criteria toward biologically driven, precision multidisciplinary therapy validated by prospective trials.